5-Azacitidine in Low-risk Myelodysplastic Syndromes (MDSs)

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2014

Conditions
Myelodysplastic Syndrome
Interventions
DRUG

Azacytidine

Azacitidine will be given at a dose of 75mg/sqm subcutaneous daily for 5 consecutive days every 28 days (every month) for a total of 8 courses. 5-Aza dosages will be adjusted

Trial Locations (7)

25123

Chair of Haematology, Bone Marrow Transplant Unit, Brescia

Unknown

University of Bologna, Bologna

Cremona, Cremona

University of Genova, Genova

Mantova, Mantova

University of Siena, Siena

University of Udine, Udine

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

University of Udine

OTHER

collaborator

University of Bologna

OTHER

collaborator

University of Genova

OTHER

collaborator

University of Siena

OTHER

collaborator

Cremona

UNKNOWN

collaborator

Mantova

UNKNOWN

lead

Università degli Studi di Brescia

OTHER